These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19888794)

  • 1. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.
    Shih YC; Pan IW; Tsai YW
    Pharmacoeconomics; 2009; 27(11):947-61. PubMed ID: 19888794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
    Campbell HE; Epstein D; Bloomfield D; Griffin S; Manca A; Yarnold J; Bliss J; Johnson L; Earl H; Poole C; Hiller L; Dunn J; Hopwood P; Barrett-Lee P; Ellis P; Cameron D; Harris AL; Gray AM; Sculpher MJ
    Eur J Cancer; 2011 Nov; 47(17):2517-30. PubMed ID: 21741831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
    Norum J; Holtmon M
    Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D; Redaelli A
    Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
    Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
    Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
    Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
    Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.
    Bocci G; Tuccori M; Emmenegger U; Liguori V; Falcone A; Kerbel RS; Del Tacca M
    Ann Oncol; 2005 Aug; 16(8):1243-52. PubMed ID: 15905308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
    Norum J
    Acta Oncol; 2000; 39(1):33-9. PubMed ID: 10752651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.